IMMUNODEFICIENCIES HIV2 324 PHT Dr. Sarah I. Bukhari PhD in Clinical Microbiology Department of Pharmaceutics Office: rd floor
Objective: Describe immunodeficiency Types of immunodeficiency diseases HIV Origin and history Structure Pathogeneicity Stages of HIV infection
Resistance to HIV Infection HIV stimulates an initial strong and effective immune response A few months after infection, virus level decline HIV infection progress Virus proliferates
Survival with HIV Infection
Exposed, But Not Infected, Population Deletion in CCR5 Effective CTLs Long-Term Nonprogressors Free of symptoms and do not progress to the stage of AIDS Unknown mechanism
Diagnostic methods ELISA: detecting HIV antibodies Western blot Plasma viral loads detect viral RNA use methods such as PCR
HIV Transmission HIV survives 6 h outside a cell and < 1.5 d inside a cell Infected body fluids transmit HIV via Sexual contact Breast milk Transplacental infection of fetus Blood-contaminated needles Organ transplants Artificial insemination Blood transfusion In developed countries, blood transfusions are not a likely source of infection anymore
AIDS Worldwide
AIDS Prevention Condoms and sterile needles! Health care workers use Universal Precautions: Wear gloves, gowns, masks, and goggles Do not recap needles Risk of infection from infected needle stick injury is 0.3%
Treatments
HIV vaccines Vaccine difficulties due to quickly integrate into the DNA of the host cell Mutations Geographical clades Antibody-binding sites “hidden” Infected cells not susceptible to CTLs Proviruses and latent viruses
AIDS Chemotherapy Treatment has much improved with HAART Highly Active Anti-Retroviral Therapy-drug combinations) Nucleoside reverse transcriptase inhibitors NRTIs (mostly nucleoside analogs,e.g azidothymidine,AZT) Non-nucleoside reverse transcriptase inhibitors NNRTI, e.g efavirenz Protease inhibitors e.g indinavir Cell Entry Inhibitors: Fusion inhibitors e.g enfuvirtide CCR5 blocker e.g maraviroc Integrase Inhibitors e.g Raltegravir
Thank you